Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) Income from Continuing Operations (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Income from Continuing Operations data on record, last reported at 51499000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 33.4% year-over-year to 51499000.0; the TTM value through Sep 2025 reached 28553000.0, up 58.47%, while the annual FY2024 figure was 3930000.0, 114.95% up from the prior year.
  • Income from Continuing Operations reached 51499000.0 in Q3 2025 per ZBIO's latest filing, up from 52223000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 108742000.0 in Q4 2024 and bottomed at 52223000.0 in Q2 2025.
  • Average Income from Continuing Operations over 3 years is 12164000.0, with a median of 35775000.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: crashed 208.37% in 2024, then decreased 20.77% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 35624000.0 in 2023, then skyrocketed by 205.25% to 108742000.0 in 2024, then tumbled by 147.36% to 51499000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 51499000.0 in Q3 2025, 52223000.0 in Q2 2025, and 33573000.0 in Q1 2025.